Should I buy or sell 10x Genomics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TXG shares. View TXG analyst ratings or view top-rated stocks .

What is 10x Genomics' stock price target for 2024?

9 equities research analysts have issued 1 year target prices for 10x Genomics' shares. Their TXG share price targets range from $45.00 to $75.00. On average, they expect the company's stock price to reach $60.22 in the next twelve months. This suggests a possible upside of 115.5% from the stock's current price. View analysts price targets for TXG or view top-rated stocks among Wall Street analysts .

How have TXG shares performed in 2024?

10x Genomics' stock was trading at $55.96 at the beginning of the year. Since then, TXG stock has decreased by 50.1% and is now trading at $27.94. View the best growth stocks for 2024 here .

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our TXG earnings forecast .

How can I listen to 10x Genomics' earnings call?

10x Genomics will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) announced its quarterly earnings data on Thursday, February, 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.05. The company had revenue of $183.98 million for the quarter, compared to the consensus estimate of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative trailing twelve-month return on equity of 28.82%. The company's revenue was up 17.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.15) earnings per share.

What ETFs hold 10x Genomics' stock?

ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Sprott Junior Gold Miners ETF (SGDJ) , ARK Genomic Revolution ETF (ARKG) , Global X Genomics & Biotechnology ETF (GNOM) , Sprott Gold Miners ETF (SGDM) , U.S. Global GO GOLD and Precious Metal Miners ETF (GOAU) , ARK Innovation ETF (ARKK) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Fidelity Disruptive Medicine ETF (FMED) .

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $670.0 million-$690.0 million, compared to the consensus revenue estimate of $702.1 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com . Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

10x Genomics (TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (3.04%), Mirador Capital Partners LP (0.02%), Banque Cantonale Vaudoise (0.01%), Handelsinvest Investeringsforvaltning (0.00%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson , Bradford Crutchfield , James Wilbur , John R Stuelpnagel, John R Stuelpnagel , Justin J Mcanear, Justin J Mcanear , Mathai Mammen , Serge Saxonov and Sridhar Kosaraju . View institutional ownership trends .

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free TXG Stock Alerts

$27.94

-1.01 (-3.49%)

(As of 04/19/2024 ET)

Compare

Today's Range: $27.59
▼
$29.45
50-Day Range: $28.95
▼
$49.54
52-Week Range: $26.75
▼
$63.57

Volume: 2.08 million shs
Average Volume: 1.46 million shs
Market Capitalization: $3.33 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $60.22

Get 10x Genomics alerts:

10x Genomics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 115.5% Upside
$60.22 Price Target
Short Interest: Bearish
7.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.40
Based on 9 Articles This Week
Insider Trading: Selling Shares
$592,806 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.47) to ($0.79) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.23 out of 5 stars

Medical Sector

133rd out of 911 stocks

Analytical Instruments Industry

5th out of 26 stocks

3.4

Analyst's Opinion

Consensus Rating
10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
10x Genomics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.15% of the outstanding shares of 10x Genomics have been sold short.
Short Interest Ratio / Days to Cover
10x Genomics has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in 10x Genomics has recently decreased by 0.70%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
10x Genomics does not currently pay a dividend.
Dividend Growth
10x Genomics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
10x Genomics has received a 76.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "Workflow automation software for clinical laboratories" products. See details.
Environmental Sustainability
The Environmental Impact score for 10x Genomics is -0.73.

2.4

News and Social Media Coverage

News Sentiment
10x Genomics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for 10x Genomics this week, compared to 4 articles on an average week.
Search Interest
13 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $592,806.00 in company stock.
Percentage Held by Insiders
10.65% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for 10x Genomics are expected to grow in the coming year, from ($1.47) to ($0.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 10x Genomics is -12.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 10x Genomics is -12.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
10x Genomics has a P/B Ratio of 4.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About 10x Genomics Stock (NASDAQ:TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TXG Stock News Headlines

April 19, 2024 | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Shares Gap Down on Analyst Downgrade

April 17, 2024 | finance.yahoo.com

10x Genomics, Inc. (TXG)

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 12, 2024 | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Shares Gap Down After Analyst Downgrade

April 11, 2024 | investing.com

Cathie Wood's ARK focuses on Teladoc and 10X Genomics stock

April 11, 2024 | americanbankingnews.com

10x Genomics (NASDAQ:TXG) Price Target Cut to $45.00 by Analysts at Barclays

April 10, 2024 | finance.yahoo.com

10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024

April 10, 2024 | prnewswire.com

10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 26, 2024 | finance.yahoo.com

10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay

March 23, 2024 | finanznachrichten.de

10x Genomics, Inc: 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

March 21, 2024 | finance.yahoo.com

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

March 16, 2024 | ca.finance.yahoo.com

TXG Nov 2024 40.000 put

March 16, 2024 | ca.finance.yahoo.com

TXG Aug 2024 60.000 call

March 16, 2024 | ca.finance.yahoo.com

TXG Dec 2024 40.000 put

March 16, 2024 | finance.yahoo.com

TXG Apr 2024 60.000 call

March 16, 2024 | finance.yahoo.com

TXG Apr 2024 40.000 put

March 14, 2024 | finanznachrichten.de

10x Genomics, Inc: 10x Genomics Begins Commercial Shipments of Chromium GEM-X Products

March 13, 2024 | msn.com

10x Genomics begins shipping Chromium GEM-X products

March 13, 2024 | finance.yahoo.com

10x Genomics Begins Commercial Shipments of Chromium GEM-X Products

March 11, 2024 | finance.yahoo.com

TXG Mar 2024 30.000 call

March 1, 2024 | investorplace.com

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

February 28, 2024 | bizjournals.com

NanoString scores legal victory in patent fight with competitor

February 27, 2024 | fool.com

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

February 20, 2024 | finance.yahoo.com

10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference

February 20, 2024 | prnewswire.com

10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference

February 16, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Travere Therapeutics (TVTX) and 10x Genomics (TXG)

See More Headlines

Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:TXG
CUSIP: N/A
CIK: 1770787
Web: www.10xgenomics.com
Phone: 925-401-7300
Fax: N/A
Employees: 1,259
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $60.22
High Stock Price Target: $75.00
Low Stock Price Target: $45.00
Potential Upside/Downside: +115.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-255,100,000.00
Net Margins: -41.17%
Pretax Margin: -40.21%
Return on Equity: -28.82%
Return on Assets: -22.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.69
Quick Ratio: 4.11

Sales & Book Value

Annual Sales: $618.73 million
Price / Sales: 5.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.22 per share
Price / Book: 4.49

Miscellaneous

Outstanding Shares: 119,170,000
Free Float: 106,476,000
Market Cap: $3.33 billion
Optionable: Optionable
Beta: 1.90

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Serge Saxonov Ph.D. (Age 47)
Co-Founder, CEO & Director
Comp: $837.68k
Dr. Benjamin J. Hindson Ph.D. (Age 49)
Co-Founder, President, Chief Scientific Officer & Director
Comp: $615.96k
Mr. Justin J. McAnear (Age 48)
Chief Financial Officer
Comp: $535.91k
Mr. Eric S. Whitaker Esq. (Age 57)
Chief Legal Officer
Comp: $558.97k
Mr. Michael Schnall-Levin
Founding Scientist & CTO
Ms. Cassie Corneau
Manager of Investor Relations and Strategic Finance
Ms. Rebecca Port
Chief People Officer
Mr. James Bryant
Director of Legal
Mr. Nikhil Rao
Director of Product Management
Mr. Florian Baumgartner
Senior Product Manager

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TXG Stock Analysis - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings or view top-rated stocks.
What is 10x Genomics' stock price target for 2024?: 9 equities research analysts have issued 1 year target prices for 10x Genomics' shares. Their TXG share price targets range from $45.00 to $75.00. On average, they expect the company's stock price to reach $60.22 in the next twelve months. This suggests a possible upside of 115.5% from the stock's current price.
View analysts price targets for TXG or view top-rated stocks among Wall Street analysts.
How have TXG shares performed in 2024?: 10x Genomics' stock was trading at $55.96 at the beginning of the year. Since then, TXG stock has decreased by 50.1% and is now trading at $27.94.
View the best growth stocks for 2024 here.
When is 10x Genomics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our TXG earnings forecast.
How can I listen to 10x Genomics' earnings call?: 10x Genomics will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were 10x Genomics' earnings last quarter?: 10x Genomics, Inc. (NASDAQ:TXG) announced its quarterly earnings data on Thursday, February, 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.05. The company had revenue of $183.98 million for the quarter, compared to the consensus estimate of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative trailing twelve-month return on equity of 28.82%. The company's revenue was up 17.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.15) earnings per share.

What ETFs hold 10x Genomics' stock?: ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Sprott Junior Gold Miners ETF (SGDJ), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), Sprott Gold Miners ETF (SGDM), U.S. Global GO GOLD and Precious Metal Miners ETF (GOAU), ARK Innovation ETF (ARKK), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Fidelity Disruptive Medicine ETF (FMED).
What guidance has 10x Genomics issued on next quarter's earnings?: 10x Genomics issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $670.0 million-$690.0 million, compared to the consensus revenue estimate of $702.1 million.
What is Serge Saxonov's approval rating as 10x Genomics' CEO?: 25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
When did 10x Genomics IPO?: 10x Genomics (TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.
Who are 10x Genomics' major shareholders?: 10x Genomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (3.04%), Mirador Capital Partners LP (0.02%), Banque Cantonale Vaudoise (0.01%), Handelsinvest Investeringsforvaltning (0.00%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends.
How do I buy shares of 10x Genomics?: Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXG) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

10x Genomics (TXG) Stock Price, News & Analysis

10x Genomics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About 10x Genomics Stock (NASDAQ:TXG)

TXG Stock Price History

TXG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TXG Stock Analysis - Frequently Asked Questions

Overall MarketRank^™